Literature DB >> 1850910

Characterization of 3'-to 5'-exonuclease activity associated with Epstein-Barr virus DNA polymerase.

T Tsurumi1.   

Abstract

Epstein-Barr virus (EBV) DNA polymerase mediates viral DNA replication during the lytic phase of the EB virus life cycle. In order to characterize its enzymatic activities EBV DNA polymerase was purified more than 1200-fold from chemically induced B95-8 cells. One polypeptide with molecular weight of 110,000 corresponded to the predicted EBV DNA polymerase, whereas the other polypeptides did not. A 3'-to-5' exonuclease activity was copurified with the EBV DNA polymerase through the course of the purification. Unlike HSV DNA DNA polymerase, 5'-to-3' exonuclease activity was not associated with the EBV DNA polymerase on the final step chromatography of single-stranded DNA agarose column. The associated 3'-to-5' exonuclease activity was stimulated by ammonium sulfate like the polymerase activity. It exhibited DNA-dependent nucleotide turnover activity and preferentially excised a terminal mismatched nucleotide on hybridized polynucleotides compared to the correctly paired substrate, indicating that the 3'-to-5' exonuclease may play a role in proofreading in the polymerization process.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1850910     DOI: 10.1016/0042-6822(91)90685-5

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  11 in total

1.  The Epstein-Barr virus pol catalytic subunit physically interacts with the BBLF4-BSLF1-BBLF2/3 complex.

Authors:  K Fujii; N Yokoyama; T Kiyono; K Kuzushima; M Homma; Y Nishiyama; M Fujita; T Tsurumi
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  3' to 5' exonuclease activity of herpes simplex virus type 1 DNA polymerase modulates its strand displacement activity.

Authors:  Yali Zhu; Kelly S Trego; Liping Song; Deborah S Parris
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

3.  Crystal structure of epstein-barr virus DNA polymerase processivity factor BMRF1.

Authors:  Kazutaka Murayama; Sanae Nakayama; Miyuki Kato-Murayama; Ryogo Akasaka; Naomi Ohbayashi; Yuki Kamewari-Hayami; Takaho Terada; Mikako Shirouzu; Tatsuya Tsurumi; Shigeyuki Yokoyama
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

4.  Primer terminus recognition and highly processive replication by Epstein-Barr virus DNA polymerase.

Authors:  T Tsurumi
Journal:  Biochem J       Date:  1991-12-15       Impact factor: 3.857

5.  Purification and characterization of the DNA-binding activity of the Epstein-Barr virus DNA polymerase accessory protein BMRF1 gene products, as expressed in insect cells by using the baculovirus system.

Authors:  T Tsurumi
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

6.  Functional expression and characterization of the Epstein-Barr virus DNA polymerase catalytic subunit.

Authors:  T Tsurumi; A Kobayashi; K Tamai; T Daikoku; R Kurachi; Y Nishiyama
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

7.  Functional interaction between Epstein-Barr virus DNA polymerase catalytic subunit and its accessory subunit in vitro.

Authors:  T Tsurumi; T Daikoku; R Kurachi; Y Nishiyama
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

8.  Further characterization of the interaction between the Epstein-Barr virus DNA polymerase catalytic subunit and its accessory subunit with regard to the 3'-to-5' exonucleolytic activity and stability of initiation complex at primer terminus.

Authors:  T Tsurumi; T Daikoku; Y Nishiyama
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

9.  Functional characterization of partially purified Epstein-Barr virus DNA polymerase expressed in the baculovirus system.

Authors:  J C Lin; B K De; E C Mar
Journal:  Virus Genes       Date:  1994-07       Impact factor: 2.332

10.  Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents.

Authors:  N S Lurain; K D Thompson; E W Holmes; G S Read
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.